Saturday, 27 May 2017

Welcome in NeoVanc

NeoVanc project aims at adapting an off-patent medicine to the specific need of paediatric populations: in specific to develop an optimal dosing and monitoring regimen for vancomycin use in preterm neonates and infants under 3 months of age in order to be able to register it for use in this age group with a PUMA. 


This project has been funded with the support of the European Commission under the FP7 programme.

Login:

Reserved Access to the our services for our Partners.

Latest:

13/05/2016 - News & Events

The 4th Consortium Meeting (NGC) and 1st Investigators Meeting will take place in Rome on the 6th and 7th June 2016

The 4th Consortium Meeting (NGC) and 1st Investigators Meeting will take place in the beautiful city…
Read more

Copyright © NeoVanc | All rights reserved. Read the disclaimer.
This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no: 602041
Call: FP7-HEALTH-2013-INNOVATION-1
Privacy policy | Cookie policy

E-mail: website@neovanc.org